[Lecture Report] The Pharmaceutical Manufacturers Association of Japan Media Forum – “Preparing for Antimicrobial Resistance (AMR) Awareness Month” (November 8, 2022)
Health and Global Policy Institute (HGPI) Manager Ms. Yui Kohno gave a lecture titled, “Efforts of AMR Alliance Japan” at the Pharmaceutical Manufacturers Association of Japan’s Media Forum titled, “Preparing for Antimicrobial Resistance (AMR) Awareness Month.” The forum was organized by the International Committee of the Japan Pharmaceutical Manufacturers Association (JPMA) in cooperation with AMR Alliance Japan. The lecture focused on the efforts of AMR Alliance Japan undertaken for seven main themes and discussed the importance of awareness-raising activities and public collaboration.
Speakers (Titles omitted, in order of presentation)
Akiko Honda (Parliamentary Vice-Minister, Health, Labour and Welfare)
Tomohiro Onishi (Deputy Director-General, Office for COVID-19 and Other Emerging Infectious Disease Control, Cabinet Secretariat)
Kazuhiro Tateda (Committee Chairman, Joint Review Committee of the Seven Academic Societies for the Promotion of Infectious Disease Therapy and Drug Discovery; Professor, Department of Microbiology and Infectious Diseases, Toho University)
Yui Kohno (Manager, Health and Global Policy Institute)
Yusuke Ariyoshi (Leader, Infectious Disease Group Chair, Global Health Subcommittee International Affairs Committee, Japan Pharmaceutical Manufacturers Association)
■ About AMR Alliance Japan
AMR Alliance Japan is an independent platform for multi-stakeholder discussions on AMR measures that was established in November 2018. Since its establishment, AMR Alliance Japan has worked with Alliance members and partner organizations to deepen the policy debate around AMR. One result of these activities was the presentation of “AMR Alliance Japan Policy Recommendations: The Japanese Government’s Role in Promoting AMR Countermeasures” in July 2019. Moving forward, the Alliance will take every opportunity to explain these recommendations to AMR policy stakeholders and take steps toward concrete policy action on AMR.
AMR Alliance Japan was established in November 2018 as a multi-stakeholder, collaborative organization dedicated to the improvement of public health through the promotion of AMR countermeasures. As of November 2022, its members include MSD K.K., The Children and Healthcare Project, Shionogi & Co., Ltd., Sumitomo Pharma Co., Ltd., The Japanese Society of Antimicrobials for Animals, NISSUI Pharmaceutical Co., Ltd., Nippon Becton Dickinson Co., Ltd., The Japan Medical Association, The Japanese Society for Medical Mycology, The Japanese Society of Pharmaceutical Health Care and Sciences, The Japanese Society of Chemotherapy, The Japanese Society for Infection Prevention and Control, The Japanese Association for Infectious Diseases, The Japanese Society for Pediatric Infectious Diseases, The Japan Pharmaceutical Manufacturers Association, The Japanese Society of Therapeutic Drug Monitoring, The Japan Society of Hospital Pharmacists, The Pharmaceutical Society of Japan, The Japan Pharmaceutical Association, The Japanese Society for Clinical Microbiology, bioMérieux Japan Ltd., Himeji City, Pfizer Japan Inc., and Meiji Seika Pharma Co., Ltd. Health and Global Policy Institute (HGPI) serves as its secretariat.
【Seven Policy Recommendations by AMR Alliance Japan】
1. Promoting antimicrobial stewardship based on the actual situation at healthcare facilities.
2. Constructing domestic AMR surveillance and crisis management systems.
3. Enabling the further and active use of AMR screening methods and rapid diagnostic technology.
4. Supporting education on AMR for the public and medical practitioners.
5. Establishing incentive models to encourage R&D for antimicrobials.
6. Stabilizing the supply of antimicrobials.
7. International collaborations to share case studies and lessons learned on AMR domestically and abroad.